FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2468771025> ?p ?o ?g. }

• W2468771025 endingPage "1721" @default.
• W2468771025 startingPage "1721" @default.
• W2468771025 abstract "Abstract Introduction With the increased use of first generation novel therapeutic agents and extended life expectancy of multiple myeloma, patients’ Health-Related Quality of Life (HRQoL) is gaining considerable importance, including the relapsed/refractory multiple myeloma (RRMM) setting. So far, few studies have been conducted to appreciate the physical, psychological/cognitive, financial, social health impact of living with RRMM on longer term exposure to anticancer drugs. The objective of this study was to evaluate the psychometric properties of the EORTC Quality-of-Life Core Questionnaire (QLQ-C30) and QLQ-Multiple Myeloma (QLQ-MY20) in RRMM patients. Methods A European, multicenter, observational study is being conducted in RRMM patients starting 2nd or 3rd line treatment. Patients are asked to complete the QLQ-C30 and QLQ-MY20 at baseline, month 3, and month 6 or discontinuation visit. Both generic and specific modules of EORTC questionnaires are widely used to assess HRQoL and symptoms in cancer patients. The QLQ-C30 includes 15 domains (Global Health Status/QOL, Physical Functioning, Role Functioning, Emotional Functioning, Cognitive Functioning, Social Functioning, Fatigue, Nausea and Vomiting, Pain, Dyspnea, Insomnia, Appetite Loss, Constipation, Diarrhea and Financial Difficulties); and the QLQ-MY20 includes four domains (Disease Symptoms, Side-Effects of Treatment, Body Image and Future Perspective). Construct validity was evaluated at baseline by confirming the structure using multitrait analysis and by assessing clinical validity against ECOG performance status. Internal consistency reliability was evaluated at baseline using Cronbach’s alpha. Results As of June 2013, 206 patients have been enrolled in the study and included in this interim analysis. Mean age was 69 years, with 51% male, and with an average time since diagnosis of 3.4 years. A total of 90% of patients started 2nd line treatment and 10% started 3rd line treatment. Both EORTC questionnaires were well completed by patients, with 95% of patients responding to the QLQ-C30 and MY20 at baseline and 74% and 66% of patients, respectively, completing all QLQ-C30 and QLQ-MY20 items at baseline. Substantial percentages of patients reported the best possible level of HRQoL and symptoms at baseline, i.e. zero points for Appetite Loss (61%), Constipation (51%), Diarrhea (80%), Financial Difficulties (73%) and Nausea and Vomiting (73%), respectively 100 score points for Body Image (61%). The structure of multi-item QLQ-C30 and QLQ-MY20 domains was confirmed, as was the relevance of aggregation of items into domains (Table 1 ). Both QLQ-C30 and QLQ-MY20 scores were correlated to ECOG performance status (Figure 1). Conclusions This interim analysis confirmed in RRMM patients the satisfactory psychometric properties of the EORTC QLQ-C30 and QLQ-MY20 in terms of validity and reliability, already published in other cancer conditions. Psychometric properties of both questionnaires will be confirmed when repeating the analyses on the final dataset of this study. Disclosures: Leleu: Janssen: Consultancy, Honoraria; Celgene: Consultancy, Honoraria; Onyx: Consultancy, Honoraria; Leopharma: Consultancy, Honoraria; Millennium: Honoraria; Amgen: Honoraria; Novartis: Honoraria. Petrucci:Celgene: Consultancy, Honoraria; Janssen-Cilag: Consultancy, Honoraria; Bristol-Myers Squibb: Consultancy, Honoraria. Welslau:Celgene: Membership on an entity’s Board of Directors or advisory committees; Janssen: Membership on an entity’s Board of Directors or advisory committees. Bottomley:Celgene: Consultancy, Research Funding. Bacon:Celgene International: Employment, Equity Ownership. Lewis:Celgene GmbH: Employment, Equity Ownership. Gilet:Celgene: Consultancy. Arnould:Celgene: Consultancy." @default.
• W2468771025 created "2016-07-22" @default.
• W2468771025 creator A5031777632 @default.
• W2468771025 creator A5045814742 @default.
• W2468771025 creator A5048560248 @default.
• W2468771025 creator A5051698029 @default.
• W2468771025 creator A5061550633 @default.
• W2468771025 creator A5062182046 @default.
• W2468771025 creator A5069555457 @default.
• W2468771025 creator A5081280110 @default.
• W2468771025 creator A5085694490 @default.
• W2468771025 creator A5089250078 @default.
• W2468771025 creator A5091000440 @default.
• W2468771025 date "2013-11-15" @default.
• W2468771025 modified "2023-09-26" @default.
• W2468771025 title "Psychometric Performance Of The EORTC Quality-Of-Life Core Questionnaire (QLQ-C30) and QLQ-Multiple Myeloma (QLQ-MY20) In Relapsed/Refractory Multiple Myeloma (RRMM)" @default.
• W2468771025 doi "https://doi.org/10.1182/blood.v122.21.1721.1721" @default.
• W2468771025 hasPublicationYear "2013" @default.
• W2468771025 type Work @default.
• W2468771025 sameAs 2468771025 @default.
• W2468771025 citedByCount "4" @default.
• W2468771025 countsByYear W24687710252019 @default.
• W2468771025 countsByYear W24687710252021 @default.
• W2468771025 countsByYear W24687710252023 @default.
• W2468771025 crossrefType "journal-article" @default.
• W2468771025 hasAuthorship W2468771025A5031777632 @default.
• W2468771025 hasAuthorship W2468771025A5045814742 @default.
• W2468771025 hasAuthorship W2468771025A5048560248 @default.
• W2468771025 hasAuthorship W2468771025A5051698029 @default.
• W2468771025 hasAuthorship W2468771025A5061550633 @default.
• W2468771025 hasAuthorship W2468771025A5062182046 @default.
• W2468771025 hasAuthorship W2468771025A5069555457 @default.
• W2468771025 hasAuthorship W2468771025A5081280110 @default.
• W2468771025 hasAuthorship W2468771025A5085694490 @default.
• W2468771025 hasAuthorship W2468771025A5089250078 @default.
• W2468771025 hasAuthorship W2468771025A5091000440 @default.
• W2468771025 hasConcept C106906290 @default.
• W2468771025 hasConcept C126322002 @default.
• W2468771025 hasConcept C159110408 @default.
• W2468771025 hasConcept C171606756 @default.
• W2468771025 hasConcept C1862650 @default.
• W2468771025 hasConcept C2776364478 @default.
• W2468771025 hasConcept C2779951463 @default.
• W2468771025 hasConcept C70410870 @default.
• W2468771025 hasConcept C71924100 @default.
• W2468771025 hasConceptScore W2468771025C106906290 @default.
• W2468771025 hasConceptScore W2468771025C126322002 @default.
• W2468771025 hasConceptScore W2468771025C159110408 @default.
• W2468771025 hasConceptScore W2468771025C171606756 @default.
• W2468771025 hasConceptScore W2468771025C1862650 @default.
• W2468771025 hasConceptScore W2468771025C2776364478 @default.
• W2468771025 hasConceptScore W2468771025C2779951463 @default.
• W2468771025 hasConceptScore W2468771025C70410870 @default.
• W2468771025 hasConceptScore W2468771025C71924100 @default.
• W2468771025 hasIssue "21" @default.
• W2468771025 hasLocation W24687710251 @default.
• W2468771025 hasOpenAccess W2468771025 @default.
• W2468771025 hasPrimaryLocation W24687710251 @default.
• W2468771025 hasRelatedWork W2076276968 @default.
• W2468771025 hasRelatedWork W2089003843 @default.
• W2468771025 hasRelatedWork W2096912944 @default.
• W2468771025 hasRelatedWork W2352080890 @default.
• W2468771025 hasRelatedWork W2355902447 @default.
• W2468771025 hasRelatedWork W2360955809 @default.
• W2468771025 hasRelatedWork W2404733967 @default.
• W2468771025 hasRelatedWork W2435227317 @default.
• W2468771025 hasRelatedWork W2752094163 @default.
• W2468771025 hasRelatedWork W4232652152 @default.
• W2468771025 hasVolume "122" @default.
• W2468771025 isParatext "false" @default.
• W2468771025 isRetracted "false" @default.
• W2468771025 magId "2468771025" @default.
• W2468771025 workType "article" @default.